TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Nasal High Flow Oxygen Therapy for Prevention of Postoperative Hypoxemia After Abdominal Surgery: A Multicenter Randomized Controlled Trial
Brief Summary: To evaluate whether early application of nasal high flow oxygen therapy after extubation can reduce the incidence of postoperative hypoxemia (defined as a PaO2/FiO2 ratio \<300) after abdominal surgery in patients with intermediate to high risk of postoperative pulmonary complications.


Options:
A: Arm Label: Standard oxygen therapy; Type: EXPERIMENTAL; Interventions: Device: Nasal high flow cannula (OptiflowTM, MR850 heated humidified, Fisher & Paykel Healthcare, Auckland, New Zealand) | Arm Label: nasal high flow oxygen therapy; Type: OTHER; Interventions: Device: Nasal high flow cannula (OptiflowTM, MR850 heated humidified, Fisher & Paykel Healthcare, Auckland, New Zealand) | Intervention Type: DEVICE; Name: Nasal high flow cannula (OptiflowTM, MR850 heated humidified, Fisher & Paykel Healthcare, Auckland, New Zealand); Assigned to Arm(s): Standard oxygen therapy, nasal high flow oxygen therapy
B: Arm Label: CF patients HFN; Type: EXPERIMENTAL; Interventions: Device: High flow nasal oxygen cannula | Arm Label: CF patients NIV; Type: EXPERIMENTAL; Interventions: Device: Noninvasive ventilation | Intervention Type: DEVICE; Name: High flow nasal oxygen cannula; Assigned to Arm(s): CF patients HFN | Intervention Type: DEVICE; Name: Noninvasive ventilation; Assigned to Arm(s): CF patients NIV
C: Arm Label: standard oxygen group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: standard oxygen | Arm Label: High-flow nasal oxygen (HFNO) group; Type: EXPERIMENTAL; Interventions: Procedure: HFNO | Intervention Type: PROCEDURE; Name: standard oxygen; Assigned to Arm(s): standard oxygen group | Intervention Type: PROCEDURE; Name: HFNO; Assigned to Arm(s): High-flow nasal oxygen (HFNO) group
D: Arm Label: HFNT; Type: EXPERIMENTAL; Interventions: Other: HFNT | Arm Label: NIV; Type: ACTIVE_COMPARATOR; Interventions: Other: NIV | Intervention Type: OTHER; Name: HFNT; Assigned to Arm(s): HFNT | Intervention Type: OTHER; Name: NIV; Assigned to Arm(s): NIV

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Nasal High Flow Oxygen Therapy for Prevention of Postoperative Hypoxemia After Abdominal Surgery: A Multicenter Randomized Controlled Trial
Brief Summary: To evaluate whether early application of nasal high flow oxygen therapy after extubation can reduce the incidence of postoperative hypoxemia (defined as a PaO2/FiO2 ratio \<300) after abdominal surgery in patients with intermediate to high risk of postoperative pulmonary complications.


Options:
A: Arm Label: BIPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: Non invasive ventilation (VNI) | Arm Label: OPTIFLOW; Type: EXPERIMENTAL; Interventions: Device: Non invasive ventilation | Intervention Type: DEVICE; Name: Non invasive ventilation (VNI); Assigned to Arm(s): BIPAP | Intervention Type: DEVICE; Name: Non invasive ventilation; Assigned to Arm(s): OPTIFLOW
B: Arm Label: Standard oxygen therapy; Type: EXPERIMENTAL; Interventions: Device: Nasal high flow cannula (OptiflowTM, MR850 heated humidified, Fisher & Paykel Healthcare, Auckland, New Zealand) | Arm Label: nasal high flow oxygen therapy; Type: OTHER; Interventions: Device: Nasal high flow cannula (OptiflowTM, MR850 heated humidified, Fisher & Paykel Healthcare, Auckland, New Zealand) | Intervention Type: DEVICE; Name: Nasal high flow cannula (OptiflowTM, MR850 heated humidified, Fisher & Paykel Healthcare, Auckland, New Zealand); Assigned to Arm(s): Standard oxygen therapy, nasal high flow oxygen therapy
C: Arm Label: CF patients HFN; Type: EXPERIMENTAL; Interventions: Device: High flow nasal oxygen cannula | Arm Label: CF patients NIV; Type: EXPERIMENTAL; Interventions: Device: Noninvasive ventilation | Intervention Type: DEVICE; Name: High flow nasal oxygen cannula; Assigned to Arm(s): CF patients HFN | Intervention Type: DEVICE; Name: Noninvasive ventilation; Assigned to Arm(s): CF patients NIV
D: Arm Label: High-flow nasal cannula oxygen (HFNCO); Type: EXPERIMENTAL; Interventions: Device: High-flow Nasal Cannula Oxygen (HFNCO) | Arm Label: standard oxygen therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Conventional oxygen treatment | Intervention Type: DEVICE; Name: High-flow Nasal Cannula Oxygen (HFNCO); Assigned to Arm(s): High-flow nasal cannula oxygen (HFNCO) | Intervention Type: DEVICE; Name: Conventional oxygen treatment; Assigned to Arm(s): standard oxygen therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Microcurrent in a Cardiovascular Rehabilitation Home-based Program in Patients With Acute Myocardial Infarction
Brief Summary: The aim of this study was to investigate the effects of electric stimulation (electrolipolysis) in a home-based cardiovascular rehabilitation program in patients with acute myocardial infarction


Options:
A: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Other: Exercise, Other: Cardiovascular Risk Factors | Arm Label: Exercise afther Microcurrent; Type: EXPERIMENTAL; Interventions: Other: Exercise, Device: Microcurrent, Other: Cardiovascular Risk Factors | Arm Label: Cardiovascular Risk Factors; Type: OTHER; Interventions: Other: Cardiovascular Risk Factors | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise, Exercise afther Microcurrent | Intervention Type: DEVICE; Name: Microcurrent; Assigned to Arm(s): Exercise afther Microcurrent | Intervention Type: OTHER; Name: Cardiovascular Risk Factors; Assigned to Arm(s): Cardiovascular Risk Factors, Exercise, Exercise afther Microcurrent
B: Arm Label: PBL- patient education; Type: EXPERIMENTAL; Interventions: Behavioral: PBL in patient education, Behavioral: Mailed patient information | Arm Label: Mailed patient information; Type: EXPERIMENTAL; Interventions: Behavioral: Mailed patient information | Intervention Type: BEHAVIORAL; Name: PBL in patient education; Assigned to Arm(s): PBL- patient education | Intervention Type: BEHAVIORAL; Name: Mailed patient information; Assigned to Arm(s): Mailed patient information, PBL- patient education
C: Arm Label: 12 week exercise training; Type: EXPERIMENTAL; Interventions: Behavioral: Structured exercise training | Arm Label: Conventional Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Structured exercise training; Assigned to Arm(s): 12 week exercise training
D: Arm Label: UC; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: vCRP; Type: EXPERIMENTAL; Interventions: Behavioral: vCRP | Intervention Type: BEHAVIORAL; Name: vCRP; Assigned to Arm(s): vCRP

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Telecare in Adults With Type 1 Diabetes Mellitus Treated by Insulin Pump - A Randomized Controlled Trial
Brief Summary: The purpose of this study is to determine whether Telecare can be used for efficient management of adults with Type 1 Diabetes Mellitus using insulin pump, in lieu of frequent clinic visits.


Options:
A: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Intensive care | Arm Label: Intensive Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Intensive care | Intervention Type: OTHER; Name: Intensive care; Assigned to Arm(s): Intensive Care, Usual Care
B: Arm Label: Gather app; Type: EXPERIMENTAL; Interventions: Other: Gather app | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Gather app; Assigned to Arm(s): Gather app
C: Arm Label: Telecare; Type: EXPERIMENTAL; Interventions: Other: Telecare | Arm Label: Conventional therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional therapy | Intervention Type: OTHER; Name: Telecare; Assigned to Arm(s): Telecare | Intervention Type: OTHER; Name: Conventional therapy; Assigned to Arm(s): Conventional therapy
D: Arm Label: Integrated Behavioral Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated Behavioral Care | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Integrated Behavioral Care; Assigned to Arm(s): Integrated Behavioral Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis
Brief Summary: This study was conducted to treat anemia in patients with chronic kidney disease. Anemia is a reduced number of red blood cells or hemoglobin. Hemoglobin is important for the transport of oxygen in your blood. The purpose of the study was to see if Roxadustat is both effective and safe as a treatment for anemia in patients with chronic kidney disease.


Options:
A: Arm Label: Roxadustat; Type: EXPERIMENTAL; Interventions: Drug: Roxadustat | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roxadustat; Assigned to Arm(s): Roxadustat | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: BAY85-3934 (25mg); Type: EXPERIMENTAL; Interventions: Drug: BAY85-3934 | Arm Label: BAY85-3934 (50mg); Type: EXPERIMENTAL; Interventions: Drug: BAY85-3934 | Arm Label: BAY85-3934 (75mg); Type: EXPERIMENTAL; Interventions: Drug: BAY85-3934 | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Biological: Darbepoetin alfa | Intervention Type: DRUG; Name: BAY85-3934; Assigned to Arm(s): BAY85-3934 (25mg), BAY85-3934 (50mg), BAY85-3934 (75mg) | Intervention Type: BIOLOGICAL; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa
C: Arm Label: Molidustat (BAY85-3934); Type: EXPERIMENTAL; Interventions: Drug: Molidustat (BAY85-3934) | Arm Label: Darbepoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Molidustat (BAY85-3934); Assigned to Arm(s): Molidustat (BAY85-3934) | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa
D: Arm Label: Daprodustat; Type: EXPERIMENTAL; Interventions: Drug: Daprodustat, Drug: Placebo, Drug: Iron therapy | Arm Label: rhEPO; Type: ACTIVE_COMPARATOR; Interventions: Drug: rhEPO, Drug: Placebo, Drug: Iron therapy | Intervention Type: DRUG; Name: Daprodustat; Assigned to Arm(s): Daprodustat | Intervention Type: DRUG; Name: rhEPO; Assigned to Arm(s): rhEPO | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Daprodustat, rhEPO | Intervention Type: DRUG; Name: Iron therapy; Assigned to Arm(s): Daprodustat, rhEPO

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fibromyalgia Activity Study With Transcutaneous Electrical Nerve Stimulation
Brief Summary: Pain associated with fibromyalgia interferes with daily function, work, and social activities resulting in a decreased quality of life. People with fibromyalgia also have a significant amount of fatigue and a fear of movement. People with fibromyalgia show enhanced excitability of pain neurons in the central nervous system and reduced pain inhibition. Therefore, one of the main treatments for patients with fibromyalgia must focus on pain relief to allow the person to function more independently both at home and at work. Transcutaneous electrical nerve stimulation is used by health professionals to deliver electrical stimulation through the skin for pain control. Basic science studies, from the PI's laboratory show that TENS activates descending pain inhibitory pathways to inhibit excitability of pain neurons. Thus the ideal patient population for the treatment of TENS would be one in which there is enhanced central excitability and reduced inhibition; fibromyalgia is such a condition.

Hypothesis: The investigators hypothesize that application of Transcutaneous Electrical Nerve Stimulation (TENS) to patients with fibromyalgia will reduce resting and movement-related pain and reduce central excitability by restoring diffuse noxious inhibitory controls (DNIC), and that this decrease in pain and/or central excitability will reduce fatigue and fear of movement, thereby improving function and quality of life


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 4
B: Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
C: Arm Label: ActiveTENS; Type: ACTIVE_COMPARATOR; Interventions: Device: TENS | Arm Label: Placebo TENS; Type: PLACEBO_COMPARATOR; Interventions: Device: TENS | Arm Label: No TENS (Standard Care); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: TENS; Assigned to Arm(s): ActiveTENS, Placebo TENS
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: D; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): C | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): D

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2 Study of the Efficacy of Antioxidant Therapy Compared With Enalapril in Slowing the Progression of Sickle Nephropathy in Children
Brief Summary: The purpose of this study is to determine whether enalapril or antioxidant therapy (N-Acetylcysteine) is effective in reducing microalbuminuria in children with sickle cell disease and and its progression to sickle nephropathy


Options:
A: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Enalapril | Intervention Type: DRUG; Name: Enalapril; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Patients With Prior Hydroxyurea; Type: N/A; Interventions: N/A | Arm Label: Patients Without Prior Hydroxyurea; Type: N/A; Interventions: N/A
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Enalapril; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enalapril | Arm Label: N-Acetylcysteine; Type: ACTIVE_COMPARATOR; Interventions: Drug: N-Acetylcysteine | Intervention Type: DRUG; Name: Enalapril; Assigned to Arm(s): Enalapril | Intervention Type: DRUG; Name: N-Acetylcysteine; Assigned to Arm(s): N-Acetylcysteine
D: Arm Label: Hydroxyurea; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Hydroxyurea | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Open-Label Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
Brief Summary: The purpose of this study is to determine which patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib.


Options:
A: Arm Label: Olaparib 300mg tablets; Type: EXPERIMENTAL; Interventions: Drug: Olaparib 300mg tablets | Arm Label: Placebo tablets; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to match olaparib 300mg | Intervention Type: DRUG; Name: Olaparib 300mg tablets; Assigned to Arm(s): Olaparib 300mg tablets | Intervention Type: DRUG; Name: Placebo to match olaparib 300mg; Assigned to Arm(s): Placebo tablets
B: Arm Label: Ovarian cancer; Type: EXPERIMENTAL; Interventions: Drug: Oral rucaparib | Intervention Type: DRUG; Name: Oral rucaparib; Assigned to Arm(s): Ovarian cancer
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: olaparib, Drug: paclitaxel, Drug: Drug: carboplatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: paclitaxel, Drug: carboplatin | Intervention Type: DRUG; Name: olaparib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Drug: carboplatin; Assigned to Arm(s): 1
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liposomal Doxorubicin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: AZD2281 | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Liposomal Doxorubicin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: AZD2281; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Open-Label Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
Brief Summary: The purpose of this study is to determine which patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib.


Options:
A: Arm Label: experimental group; Type: EXPERIMENTAL; Interventions: Drug: apatinib | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebos | Intervention Type: DRUG; Name: apatinib; Assigned to Arm(s): experimental group | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): control group
B: Arm Label: DOXIL + trabectedin; Type: EXPERIMENTAL; Interventions: Drug: Trabectedin, Drug: DOXIL, Drug: Dexamethasone | Arm Label: DOXIL; Type: ACTIVE_COMPARATOR; Interventions: Drug: DOXIL | Intervention Type: DRUG; Name: Trabectedin; Assigned to Arm(s): DOXIL + trabectedin | Intervention Type: DRUG; Name: DOXIL; Assigned to Arm(s): DOXIL, DOXIL + trabectedin | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): DOXIL + trabectedin
C: Arm Label: Arm I (cediranib maleate and olaparib); Type: EXPERIMENTAL; Interventions: Procedure: Biopsy Procedure, Procedure: Biospecimen Collection, Drug: Cediranib Maleate, Procedure: Computed Tomography, Procedure: Echocardiography Test, Procedure: Magnetic Resonance Imaging, Procedure: Multigated Acquisition Scan, Drug: Olaparib | Arm Label: Arm II (olaparib); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Biopsy Procedure, Procedure: Biospecimen Collection, Procedure: Computed Tomography, Procedure: Echocardiography Test, Procedure: Magnetic Resonance Imaging, Procedure: Multigated Acquisition Scan, Drug: Olaparib | Intervention Type: PROCEDURE; Name: Biopsy Procedure; Assigned to Arm(s): Arm I (cediranib maleate and olaparib), Arm II (olaparib) | Intervention Type: PROCEDURE; Name: Biospecimen Collection; Assigned to Arm(s): Arm I (cediranib maleate and olaparib), Arm II (olaparib) | Intervention Type: DRUG; Name: Cediranib Maleate; Assigned to Arm(s): Arm I (cediranib maleate and olaparib) | Intervention Type: PROCEDURE; Name: Computed Tomography; Assigned to Arm(s): Arm I (cediranib maleate and olaparib), Arm II (olaparib) | Intervention Type: PROCEDURE; Name: Echocardiography Test; Assigned to Arm(s): Arm I (cediranib maleate and olaparib), Arm II (olaparib) | Intervention Type: PROCEDURE; Name: Magnetic Resonance Imaging; Assigned to Arm(s): Arm I (cediranib maleate and olaparib), Arm II (olaparib) | Intervention Type: PROCEDURE; Name: Multigated Acquisition Scan; Assigned to Arm(s): Arm I (cediranib maleate and olaparib), Arm II (olaparib) | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Arm I (cediranib maleate and olaparib), Arm II (olaparib)
D: Arm Label: Ovarian cancer; Type: EXPERIMENTAL; Interventions: Drug: Oral rucaparib | Intervention Type: DRUG; Name: Oral rucaparib; Assigned to Arm(s): Ovarian cancer

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Open-Label Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
Brief Summary: The purpose of this study is to determine which patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib.


Options:
A: Arm Label: Ovarian cancer; Type: EXPERIMENTAL; Interventions: Drug: Oral rucaparib | Intervention Type: DRUG; Name: Oral rucaparib; Assigned to Arm(s): Ovarian cancer
B: Arm Label: Vintafolide + PLD; Type: EXPERIMENTAL; Interventions: Drug: Vintafolide, Drug: pegylated liposomal doxorubicin (PLD), Other: EC20 | Arm Label: PLD Alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: pegylated liposomal doxorubicin (PLD), Other: EC20 | Intervention Type: DRUG; Name: Vintafolide; Assigned to Arm(s): Vintafolide + PLD | Intervention Type: DRUG; Name: pegylated liposomal doxorubicin (PLD); Assigned to Arm(s): PLD Alone, Vintafolide + PLD | Intervention Type: OTHER; Name: EC20; Assigned to Arm(s): PLD Alone, Vintafolide + PLD
C: Arm Label: Lead-in Stage - cabozantinib (XL184); Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib | Arm Label: Randomized Stage - cabozantinib (XL184); Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib | Arm Label: Randomized Stage - placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Open-Label Extension - cabozantinib (XL184); Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib | Arm Label: Non-Randomized Expansion (NRE) Cohort - Castrate Resistant Prostate Cancer (CRPC), 100mg; Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib | Arm Label: Non-Randomized Expansion (NRE) Cohort - Castrate Resistant Prostate Cancer (CRPC), 39.4mg; Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib | Arm Label: A. Non-Randomized Expansion (NRE) Cohort - Ovarian; Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib | Intervention Type: DRUG; Name: Cabozantinib; Assigned to Arm(s): A. Non-Randomized Expansion (NRE) Cohort - Ovarian, Lead-in Stage - cabozantinib (XL184), Non-Randomized Expansion (NRE) Cohort - Castrate Resistant Prostate Cancer (CRPC), 100mg, Non-Randomized Expansion (NRE) Cohort - Castrate Resistant Prostate Cancer (CRPC), 39.4mg, Open-Label Extension - cabozantinib (XL184), Randomized Stage - cabozantinib (XL184) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Randomized Stage - placebo
D: Arm Label: paclitaxel and pazopanib; Type: EXPERIMENTAL; Interventions: Drug: paclitaxel, Drug: pazopanib | Arm Label: paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: paclitaxel | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): paclitaxel, paclitaxel and pazopanib | Intervention Type: DRUG; Name: pazopanib; Assigned to Arm(s): paclitaxel and pazopanib

Answer: A